Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2022, 31(5):329-333

Coronary artery aneurysm after Kawasaki disease

Fabo P1,2, Olejnik P1,2
1 Department of Paediatric Cardiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia and
2 Department of Paediatric Cardiology, Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases of Slovak Republic, Bratislava, Slovakia

The complication of coronary artery aneurysm development after Kawasaki disease is currently not common after introducing human immunoglobulin therapy. Still, it is a life-threatening complication requiring consistent life-long follow-up to avoid acute coronary syndrome. We present a case report of a Kawasaki disease patient with initial large coronary artery aneurysm regressing to medium size coronary artery aneurysm. Based on the recent recommendation from the American Heart Association for Kawasaki disease management, an adequate thromboprophylaxis was set in this patient.

Keywords: Kawasaki disease; coronary artery aneurysm; thromboprophylaxis; long-term follow-up

Published: May 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fabo P, Olejnik P. Coronary artery aneurysm after Kawasaki disease. Cardiology Letters. 2022;31(5-6):329-333.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol. 2010;20:302. Go to original source...
    2. Holman R, Belay E, Christensen K, Folkema A, Steiner C, Schonberger L. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29:483. Go to original source...
    3. Bar-Meir M, Haklai Z, Dor M. Kawasaki disease in Israel. Pediatr Infect Dis J. 2011;30:589. Go to original source...
    4. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Originally published 29 Mar 2017, Correction 29 Jul 2019. Circulation. 2019;140:e181-e184.
    5. Nakamura Y, Yanagawa H, Kato H, Harada K, Kawasaki T. Mortality among patients with history of Kawasaki disease: the third look. The Kawasaki Disease Follow-up Group. Acta Paediatr Jpn. 1998;40:419. Go to original source...
    6. Son M, Gauvreau K, Ma L, Baker A, Sundel R, Fulton D, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1. Go to original source...
    7. Newburg J, Takahashi M, Burns J, Beiser A, Chung K, Duffy C, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347. Go to original source...
    8. Newburger J, Takahashi M, Gerber M, Gewitz M, Tani L, Burns J, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association. Circulation. 2004;110:2747. Go to original source...
    9. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055. Go to original source...
    10. Newburger J, Takahashi M, Burns J, Beiser A, Chung K, Duffy C, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341 Go to original source...
    11. Hirohisa K, Tetsu S, Teiji A, Noboru S, Kanoko H, Yasuki M. Long-term consequences of Kawasaki disease. Circulation. 1996;94:1379-1385. Go to original source...
    12. Tsuda E, Hashimoto S. Time course of coronary artery aneurysms in Kawasaki disease. J Pediatr. 2021 Mar; 230:133-139e2. Go to original source...
    13. Abbassi V. Growth and normal puberty. Pediatrics. 1998;102(2 Pt 3):507. Go to original source...
    14. Orenstein J, Shulman S, Fox L, Baker S, Takahashi M, Bhatti T, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One. 2012;7:e38998. Go to original source...
    15. Manlhiot C, Brandão LR, Somji Z, Chesney AL, MacDonald C, Gurofsky RC, et al. Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol 2010 Aug;31:834-842. Go to original source...
    16. Suda K, Kudo Y, Higaki T, Nomura Y, Miura M, Matsumura M, et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J. 2009 Jul;73:1319-1323. Go to original source...
    17. Manlhiot C, Newburger JW, Low T, Dahdah N, Mackie AS, Raghuveer G. Low-molecular-weight heparin vs warfarin for thromboprophylaxis in children with coronary artery aneurysms after Kawasaki disease: A Pragmatic Registry Trial. Can J Cardiol. 2020 Oct;36:1598-1607. Go to original source...

    Return to the content